Praxis(US:PRAX)2025-05-02 14:19Pipeline and Catalysts - The company has 4 assets in late stage development[6] - Clinical readouts are expected in the next 4 quarters[6] - Topline results for the RADIANT open label study of Vormatrigine in focal onset or generalized epileptic seizures are expected by mid-2025[17, 37] - Topline results from the ESSENTIAL3 studies of Ulixacaltamide in Essential Tremor are expected in Q3 2025[17] - EMBOLD Cohort 2 topline results for Relutrigine in SCN2A GoF and SCN8A are expected in 1H 2026, with NDA filing in 2026[17] Epilepsy Portfolio - The US market opportunity for Vormatrigine in common epilepsy (3.5 million US prevalence) is estimated to be greater than $2.5 billion[20] - The US market opportunity for Relutrigine in developmental epilepsies (over 200,000 patients) is estimated to be greater than $3 billion[20] - The US market opportunity for Elsunersen in SCN2A genetically typified developmental epilepsies (~2,000 patients) is estimated to be greater than $500 million[20] - EMBRAVE Part 1 data showed a 39% mean and 43% median reduction in seizures from baseline in SCN2A GoF patients treated with Elsunersen[82] Essential Tremor - Up to 50% of Essential Tremor patients are not receiving treatment for their condition[105] - 85% of neurologist visits are for patients seeking Essential Tremor treatment[108]